Jaguar Health, Inc. (NASDAQ:JAGX) Sees Large Decrease in Short Interest

Jaguar Health, Inc. (NASDAQ:JAGX) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 35,700 shares, a decline of 96.3% from the February 28th total of 953,100 shares. Based on an average daily trading volume, of 22,800 shares, the short-interest ratio is presently 1.6 days. Approximately 0.3% of the shares of the company are sold short.

Institutional Trading of Jaguar Health

A hedge fund recently bought a new stake in Jaguar Health stock. Virtu Financial LLC purchased a new stake in Jaguar Health, Inc. (NASDAQ:JAGX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 25,591 shares of the biotechnology company’s stock, valued at approximately $35,000. Virtu Financial LLC owned approximately 0.22% of Jaguar Health at the end of the most recent reporting period. Institutional investors own 12.04% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Jaguar Health in a report on Friday. They issued a “sell” rating for the company.

Jaguar Health Price Performance

Jaguar Health stock traded down $0.24 during midday trading on Friday, hitting $5.15. 13,704 shares of the company’s stock were exchanged, compared to its average volume of 28,006. The firm’s 50 day simple moving average is $16.83 and its 200 day simple moving average is $23.42. Jaguar Health has a 12-month low of $4.90 and a 12-month high of $540.00. The company has a current ratio of 1.84, a quick ratio of 1.36 and a debt-to-equity ratio of 1.65.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.